BioCentury | Dec 22, 2014
Company News

Dutalys, Roche deal

...Roche acquired antibody developer Dutalys for $133.8 million in cash up front and up to $355...
...cash up front and up to $355 million in undisclosed milestones. Roche plans to use Dutalys’...
...will integrate Dutalys into its large molecule research unit. Dutalys did not respond to inquiries. Dutalys GmbH...
BioCentury | Dec 19, 2014
Company News

Roche to acquire Dutalys

...front. Dutalys' shareholders are eligible for $355 million in undisclosed milestones. Roche intends to use Dutalys'...
...human bi-specific and tetra-specific antibodies across a range of undisclosed therapeutic areas. Roche will integrate Dutalys...
Items per page:
1 - 2 of 2
BioCentury | Dec 22, 2014
Company News

Dutalys, Roche deal

...Roche acquired antibody developer Dutalys for $133.8 million in cash up front and up to $355...
...cash up front and up to $355 million in undisclosed milestones. Roche plans to use Dutalys’...
...will integrate Dutalys into its large molecule research unit. Dutalys did not respond to inquiries. Dutalys GmbH...
BioCentury | Dec 19, 2014
Company News

Roche to acquire Dutalys

...front. Dutalys' shareholders are eligible for $355 million in undisclosed milestones. Roche intends to use Dutalys'...
...human bi-specific and tetra-specific antibodies across a range of undisclosed therapeutic areas. Roche will integrate Dutalys...
Items per page:
1 - 2 of 2